Protocol for dissecting the aggregation-prone protein interactome with optogenetic-induced aggregation and biotin

Maxime Teixeira1, Dylan Musiol1, Jean-Philippe Lambert2

  • 1Neuroscience Research Program, CHU de Québec-Université Laval Research Center, Québec, QC, Canada; Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.

STAR Protocols
|December 28, 2025
PubMed

Insights

Researchers developed a new method to study early protein aggregation, specifically for alpha-synuclein (α-syn). This technique identifies proteins interacting with newly forming α-syn aggregates, advancing synucleinopathy research.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • The early stages of protein aggregation, especially alpha-synuclein (α-syn) aggregation, are crucial in synucleinopathies but remain poorly understood.
  • Identifying interacting proteins is key to understanding the mechanisms driving aggregate formation and disease progression.

Purpose of the Study:

  • To present a novel protocol combining light-inducible protein aggregation (LIPA) with proximity biotinylation for studying α-syn aggregation dynamics.
  • To establish a workflow for identifying proteins that interact with nascent α-syn aggregates.

Main Methods:

  • The protocol involves protein expression, purification of biotinylated proteins using an UltraID construct, and subsequent liquid chromatography-mass spectrometry (LC-MS) analysis.
  • Light-inducible protein aggregation (LIPA) was coupled with proximity biotinylation to capture transient protein interactions.

Main Results:

  • The described platform enables the identification of proteins interacting with newly formed α-syn aggregates.
  • Biochemical validation confirms the successful application of the LIPA-UltraID system.

Conclusions:

  • This combined LIPA and proximity biotinylation strategy offers a powerful approach to investigate the molecular players involved in early α-syn aggregation.
  • The protocol facilitates the discovery of novel therapeutic targets for synucleinopathies by elucidating protein interaction networks during aggregation.